Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI® (Lecanemab) For Early Alzheimer’s Disease

Canada’s health regulatory agency has issued a final positive recommendation supporting the public reimbursement of Leqembi® (lecanemab) for patients with early Alzheimer’s disease. This marks a significant policy decision aimed at improving access to an innovative treatment that has shown promise in slowing disease progression, making it a notable development for patients, caregivers, and healthcare providers across the country.

The Canadian Agency for Drugs and Technologies in Health (CADTH) announced its final recommendation on March 26, 2026, endorsing the reimbursement of Leqembi® for eligible patients diagnosed with early-stage Alzheimer’s. This follows earlier preliminary reviews and a positive health technology assessment, which evaluated the drug’s efficacy, safety, and cost-effectiveness based on clinical trial data and economic models.

The decision aligns with recent international trends toward broader access to disease-modifying therapies for Alzheimer’s, especially as new evidence suggests that early intervention can slow cognitive decline. The recommendation now moves to federal and provincial health authorities for final coverage decisions, which could take several months to implement fully. If adopted, this would provide a pathway for publicly funded access, reducing the financial burden on patients and families.

The manufacturer of Leqembi®, Eisai, has welcomed the decision, emphasizing its commitment to making the drug accessible to Canadian patients. Health officials have noted that this move could significantly impact the treatment landscape for Alzheimer’s, which currently offers limited options for early-stage intervention.

Implications for Alzheimer’s Care Accessibility in Canada

This final positive recommendation is a milestone for Alzheimer’s treatment in Canada, as it signals government support for a drug that could alter disease progression. If fully reimbursed, Leqembi® could become a standard option for early diagnosis, potentially improving quality of life for thousands of patients and easing the burden on caregivers and healthcare systems. It also reflects a shift toward valuing innovative, disease-modifying therapies within publicly funded healthcare.

However, the decision’s impact depends on subsequent policy actions, including provincial-level coverage and patient access programs. The move may also influence future drug approvals and reimbursement strategies for neurodegenerative conditions.

Background on Leqembi® and Alzheimer’s Treatment Policies

Leqembi® (lecanemab) is a monoclonal antibody developed by Eisai and Biogen, approved in several countries for early Alzheimer’s disease based on clinical trial results indicating it can slow cognitive decline. The drug has been subject to ongoing debate regarding its safety profile, cost, and real-world effectiveness.

In Canada, access to new Alzheimer’s treatments has historically been limited, with most therapies focusing on symptomatic relief rather than disease modification. Recent international approvals and emerging evidence have prompted discussions about expanding access, but Canadian regulatory and reimbursement pathways have been cautious.

The current decision follows years of advocacy from patient groups, clinicians, and researchers calling for more proactive policies to incorporate disease-modifying therapies into the public health system.

Unresolved Details on Implementation and Access

While the final recommendation is a major step, it is not yet clear how quickly provincial health authorities will implement reimbursement policies or what criteria will be used for patient eligibility. Details regarding coverage costs, patient support programs, and potential restrictions remain to be clarified. Additionally, ongoing debates about the drug’s long-term safety and cost-effectiveness could influence final coverage decisions.

Next Steps for Policy Adoption and Patient Access

Canadian health authorities, including provincial ministries, are expected to review the recommendation over the coming months. Final coverage decisions could be announced within 3 to 6 months, with implementation possibly extending into the next fiscal year. Stakeholders will be watching for details on patient eligibility, funding levels, and support programs. Meanwhile, clinicians and advocacy groups are preparing to inform patients about potential access pathways and ongoing clinical monitoring requirements.

Key Questions

What does this recommendation mean for Alzheimer’s patients in Canada?

If adopted, it could mean that eligible patients with early Alzheimer’s will have access to Leqembi® through public health insurance, reducing out-of-pocket costs and expanding treatment options.

When will patients likely start receiving Leqembi® through public reimbursement?

Final coverage policies are expected within the next 3 to 6 months, but full access might take longer depending on provincial decisions and program implementation.

Are there safety concerns related to Leqembi®?

Clinical trials have shown some safety issues, including risks of brain swelling and hemorrhage, which are being monitored. The final policy will likely include safety and monitoring guidelines.

How does this decision compare to other countries?

Several countries have approved Leqembi® and begun reimbursement, but Canada’s move marks a significant step toward broader access within North America, aligning with international trends.

What are the potential costs of reimbursing Leqembi®?

Cost estimates vary, but reimbursement could involve significant healthcare expenditures, prompting ongoing discussions about balancing innovation with sustainability.

Source: primary